Global cardiovascular risk in health care: What else shall patients and doctors talk about?;Kardiovaskuläres Gesamtrisiko in der Versorgung: Worüber Sollen Patienten und Ärzte noch Miteinander Reden?

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen

Volumn 102, Issue 6, 2008, Pages 361-365

  Donner Banzhoff, Norbert ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Blood pressure; Cardiovascular disease prevention and control; Cholesterol; Physician patient relations; Primary care

Indexed keywords

EID: 57349100913     PISSN: 18659217     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.zefq.2008.07.020     Document Type: Article

References (20)

1. Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 2006;92:1752-9.
2. Kuhn TS. Die Struktur wissenschaftlicher Revolutionen. Frankfurt am Main; Suhrkamp; 1976.
3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003 Jun 28;326:1419-521.
4. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, et al. ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008 Apr 3;358:1431-43.
5. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
6. http://www.aerzteblatt.de/V4/news/news.asp?id=31300 (abgerufen 18.4.08).
7. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
8. Fox KM. Efficacy of Perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
9. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-68.
10. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-25.
11. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events In patients with type 2 diabetes in the PROactive Study (PROspective ploglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
12. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
13. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007;116:2923-32.
14. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75.
15. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannablnoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
16. http://www.stern.de/wirtschaft/unternehmen/unternehmen/: Novartis-Freundlich,/604247.html (abgerufen 18.4.08).
17. Es handelt sich um die ENHANCE-Studie der Firmen MSD und Schering-Plough; siehe Arzneimittelbrief 2008;42:31-32.
18. http://www.arriba-hausarzte.de (abgerufen 18.4.08).
19. Jones R. Dismantling general practice. Br J Gen Pract 2007;57:860-1.
20. Donner-Banzhoff N. Betreuungsdimensionen und Verläufe. DEGAM-Serie Betreuung chronisch kranker Menschen. Z Allg med 2008;84:75-8.